Back to Search
Start Over
Bispecific antibody platforms for cancer immunotherapy.
- Source :
-
Critical Reviews in Oncology/Hematology . Dec2014, Vol. 92 Issue 3, p153-165. 13p. - Publication Year :
- 2014
-
Abstract
- Over the past decades advances in bioengineering and expanded insight in tumor immunology have resulted in the emergence of novel bispecific antibody (bsAb) constructs that are capable of redirecting immune effector cells to the tumor microenvironment. (Pre-) clinical studies of various bsAb constructs have shown impressive results in terms of immune effector cell retargeting, target dependent activation and the induction of anti-tumor responses. This review summarizes recent advances in the field of bsAb-therapy and limitations that were encountered. Furthermore, we will discuss potential future developments that can be expected to take the bsAb approach successfully forward. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 10408428
- Volume :
- 92
- Issue :
- 3
- Database :
- Academic Search Index
- Journal :
- Critical Reviews in Oncology/Hematology
- Publication Type :
- Academic Journal
- Accession number :
- 99635982
- Full Text :
- https://doi.org/10.1016/j.critrevonc.2014.08.003